finance

Shareholders question looming patent cliff and antitrust risks in potential $400bn tie-up with Bristol Myers Squibb

Bloomberg's Yiqin Shen joins Scarlet Fu and Eric Balchunas on "Bloomberg ETF IQ." Leveraged ETFs that offer the tantalizing prospect of doubling or tripling the daily returns of an individual stock are famously risky for investors who buy them. The result has been a quiet surge of activity in an exo

Swiss bank failed to implement adequate curbs despite previous sanction by US regulators

Shareholders question looming patent cliff and antitrust risks in potential $400bn tie-up with Bristol Myers Squibb

AstraZeneca tops pharma growth rankings while Bristol Myers trails amid merger talks

Acquisition strengthens $365B credit platform, bringing together Oaktree’s cycle-tested expertise with Brookfield’s scale and reach Acquisition strengthens $365B credit platform, bringing together Oaktree’s cycle-tested expertise with Brookfield’s scale and reach

Integer Holdings to go private via $5.7B acquisition by KKR

Indonesia's IPO market stalls as quality reforms deter potential issuers

Prysmian expands North American footprint with $3.8B Atkore acquisition

AstraZeneca has explored an acquisition of Bristol Myers Squibb, according to people familiar with the matter. It’s unclear if discussions are ongoing or whether they will result in a transaction, the people cautioned. A representative for AstraZeneca declined to comment and Bristol Myers Squibb cou